Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Autologous stem cell transplantation in follicular non-Hodgkin's lymphoma

Bone Marrow Transplantation volume 29, pages S1–S4 (2002)Cite this article

Abstract

The failure of conventional chemotherapy to improve overall survival rates in follicular non-Hodgkin's lymphoma (NHL) has led to the development of alternative treatment regimens. One such regimen is high-dose chemotherapy (HDT) with autologous stem cell transplantation (ASCT). In ASCT stem cells, harvested predominantly from peripheral blood, are used to repopulate the haemopoietic system after high-dose chemotherapy. Comparison of failure-free survival rates following ASCT, with those previously obtained with conventional chemotherapy, suggests a benefit for ASCT in patients who have previously responded to chemotherapy. Other factors that adversely influence the outcome of ASCT include large tumour burden and bcl-2 overexpression. Although ASCT in follicular NHL can prolong the period of remission, relapse is still common and can be caused either by contamination of the stem cell harvest with tumour cells, or regrowth of residual malignant cells not eradicated by the high-dose chemotherapy. Several strategies have been developed to reduce the rate of relapse, including in vitro purging of the stem cell product to remove tumour cells and using allogenic stem cells from HLA-matched donors with no history of malignant disease. While both these methods may have some benefit, they also have limitations. In vitro purging is labour intensive, costly and, as yet, the effect on relapse is unclear. Allogenic stem cell transplants have been associated with a reduced risk of relapse, but this is offset by increased transplant-related mortality. The most promising strategy to reduce the rate of relapse following ASCT is in vivo purging using rituximab, a monoclonal antibody to CD20. Rituximab mobilises mechanisms to kill lymphoma cells, and causes a rapid depletion of B cells from peripheral blood. Rituximab has demonstrated good efficacy as monotherapy in patients with both aggressive and indolent lymphoma and has shown very high response rates (>95%) when used in combination with HDT.

Bone Marrow Transplantation (2001) 29, Suppl. 1, S1–S4. doi:10.1038/sj.bmt.1703294

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Gallagher CJ, Gregory WM, Jones AE et al. Follicular lymphoma: prognostic factors for response and survival J Clin Oncol 1986 4: 1470 1480

    Article  CAS  PubMed  Google Scholar 

  2. Bierman PJ, Vose JM, Anderson JR et al. High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma J Clin Oncol 1997 15: 445 450

    Article  CAS  PubMed  Google Scholar 

  3. Voso MT, Pantel G, Weis M et al. In vivo depletion of B cells using a combination of high-dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non-Hodgkin's lymphoma Br J Haematol 2000 109: 729 735

    Article  CAS  PubMed  Google Scholar 

  4. Gribben JG, Freedman AS, Woo SD et al. All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment Blood 1991 78: 3275 3280

    CAS  PubMed  Google Scholar 

  5. Berinstein NL, Reis MD, Ngan BY et al. Detection of occult lymphoma in the peripheral blood and bone marrow of patients with untreated early-stage and advanced-stage follicular lymphoma J Clin Oncol 1993 11: 1344 1352

    Article  CAS  PubMed  Google Scholar 

  6. Freedman AS, Neuberg D, Mauch P et al. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma Blood 1999 94: 3325 3333

    CAS  PubMed  Google Scholar 

  7. Yerly-Motta V, Racadot E, Fest T et al. Comparative preclinical study of three bone marrow purging methods using PCR evaluation of residual t(14;18) lymphoma cells Leuk Lymphoma 1996 23: 313 321

    Article  CAS  PubMed  Google Scholar 

  8. Fouillard L, Laporte JP, Labopin M et al. Autologous stem-cell transplantation for non-Hodgkin's lymphomas: the role of graft purging and radiotherapy posttransplantation – results of a retrospective analysis on 120 patients autografted in a single institution J Clin Oncol 1998 16: 2803 2816

    Article  CAS  PubMed  Google Scholar 

  9. Martin-Henao GA, Picon M, Limon A et al. Immunomagnetic bone marrow (BM) and peripheral blood progenitor cell (PBPC) purging in follicular lymphoma (FL) Bone Marrow Transplant 1999 23: 579 587

    Article  CAS  PubMed  Google Scholar 

  10. Paulus U, Dreger P, Viehmann K et al. Purging peripheral blood progenitor cell grafts from lymphoma cells: quantitative comparison of immunomagnetic CD34+ selection systems Stem Cells 1997 15: 297 304

    Article  CAS  PubMed  Google Scholar 

  11. Bensinger WI . Should we purge? Bone Marrow Transplant 1998 21: 113 115

    Article  CAS  PubMed  Google Scholar 

  12. Horning SJ, Negrin RS, Hoppe RT et al. High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial Blood 2001 97: 404 409

    Article  CAS  PubMed  Google Scholar 

  13. Williams CD, Harrison CN, Lister TA et al. High-dose therapy and autologous stem-cell support for chemosensitive transformed low-grade follicular non-Hodgkin's lymphoma: a case-matched study from the European Bone Marrow Transplant Registry J Clin Oncol 2001 19: 727 735

    Article  CAS  PubMed  Google Scholar 

  14. Schouten HC, Kvaloy S, Sydes M et al. The CUP trial: a randomized study analyzing the efficacy of high dose therapy and purging in low-grade non-Hodgkin's lymphoma (NHL) Ann Oncol 2000 11 (Suppl. 1): 91 94

    Article  Google Scholar 

  15. van Besien KW, Khouri IF, Giralt SA et al. Allogeneic bone marrow transplantation for refractory and recurrent low-grade lymphoma: the case for aggressive management J Clin Oncol 1995 13: 1096 1102

    Article  CAS  PubMed  Google Scholar 

  16. van Besien K, Sobocinski KA, Rowlings PA et al. Allogeneic bone marrow transplantation for low-grade lymphoma Blood 1998 92: 1832 1836

    CAS  PubMed  Google Scholar 

  17. Verdonck LF . Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin's lymphoma: updated results of the Utrecht experience Leuk Lymphoma 1999 34: 129 136

    Article  CAS  PubMed  Google Scholar 

  18. Attal M, Socie G, Molina L et al. Allogeneic bone marrow transplantation for refractory and recurrent follicular lymphoma: a case-matched analysis with autologous transplantation from the French bone marrow transplant registry data Blood 1997 90 (Suppl. 1): 255a

    Google Scholar 

  19. Kelemen E, Masszi T, Remenyi P et al. Reduction in the frequency of transplant-related complications in patients with chronic myeloid leukemia undergoing BMT preconditioned with a new, non-myeloablative drug combination Bone Marrow Transplant 1998 21: 747 749

    Article  CAS  PubMed  Google Scholar 

  20. Slavin S . New strategies for bone marrow transplantation Curr Opin Immunol 2000 12: 542 551

    Article  CAS  PubMed  Google Scholar 

  21. Champlin R, Khouri I, Kornblau S et al. Reinventing bone marrow transplantation: reducing toxicity using nonmyeloablative, preparative regimens and induction of graft-versus-malignancy Curr Opin Oncol 1999 11: 87 95

    Article  CAS  PubMed  Google Scholar 

  22. Giralt S, Estey E, Albitar M et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy Blood 1997 89: 4531 4536

    CAS  PubMed  Google Scholar 

  23. Maloney DG, Liles TM, Czerwinski DK et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma Blood 1994 84: 2457 2466

    CAS  PubMed  Google Scholar 

  24. Coiffier B, Haioun C, Ketterer N et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study Blood 1998 92: 1927 1932

    CAS  PubMed  Google Scholar 

  25. McLaughlin P, Grillo-Lopez AJ, Link BK et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program J Clin Oncol 1998 16: 2825 2833

    Article  CAS  PubMed  Google Scholar 

  26. Colombat P, Salles G, Brousse N et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation Blood 2001 97: 101 106

    Article  CAS  PubMed  Google Scholar 

  27. Czuczman MS, Grillo-Lopez AJ, White CA et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy J Clin Oncol 1999 17: 268 276

    Article  CAS  PubMed  Google Scholar 

  28. Coiffier B, Lepage R, Herbrecht R et al. Elderly patients with diffuse large B-cell lymphoma (DLCL): interim results of a randomized GELA trial Blood 2000 96 (Suppl. 1): 950a

    Google Scholar 

  29. Buckstein R, Imrie K, Spaner D et al. Stem cell function and engraftment is not affected by ‘in vivo purging’ with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma Semin Oncol 1999 5 (Suppl. 14): 115 122

    Google Scholar 

  30. Salles G, Moullet I, Charlot C et al. In vivo purging with rituximab before autologous peripheral blood progenitor cell (PBPC) transplantation in lymphoma patients (pts) Blood 1999 94 (Suppl. 1): 141a

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Haematology, St George's Hospital Medical School, London, UK

    R Pettengell

Authors
  1. R Pettengell
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pettengell, R. Autologous stem cell transplantation in follicular non-Hodgkin's lymphoma. Bone Marrow Transplant 29 (Suppl 1), S1–S4 (2002). https://doi.org/10.1038/sj.bmt.1703294

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1703294

Keywords

Search

Advanced search

Quick links